| 27th November - Morning | 28th November - Morning | 29th November - Morning |
|
Session 5. Advancement in Vaccine Design for Broad Protection |
Session 3. Vaccine Adjuvants | |
| 27th November - Afternoon | 28th November - Afternoon | 29th November - Afternoon |
|
Session 1. Cancer Vaccines, Immunotherapy, and Immunoprevention |
Session 6. Novel Assays for Evaluating Responses to Vaccination |
Session 4. mRNA Vaccines |
IECV 2024 Day 1
Session 5. Advancement in Vaccine Design for Broad Protection
Date: 27th November 2024 (Wednesday)
Time: 9:00 (CET, Basel) | 03:00 (EDT, New York) | 16:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 09:00-09:15 | Professor Sara Louise Cosby Event Chair |
Welcome from the Event Chair |
| 09:15-09:45 | Prof. Dr. Martin Bachmann Keynote Speaker |
Companion animals as link for the development of therapeutic vaccines in humans |
| 9:45-10:00 | Dominik Rothen | Preclinical evaluation of novel sterically optimized VLP-based vaccines against all four DENV serotypes |
| 10:00-10:15 | Gianmarco Ferrara | An Evaluation of the humoral response following two doses of a Coxiella burnetii vaccine in water buffalo |
| 10:15-10:30 | Xinyue Chang | Virus-like particle-derived vaccine induces broad neutralising antibodies against porcine epidemic diarrhea virus (PEDV) |
| 10:30-10:45 | Victoria Jane Smyth | Evaluation of Chicken Astrovirus Breeder Vaccine Candidate |
| 10:45-11:00 | Zilu Ma | Lysosome-Associated Membrane Protein Targeting Strategy Improved Immunogenicity of Glycoprotein-Based DNA Vaccine for Hantaan virus |
| 11:00-11:15 | Dudnikova Ekaterina Nikolaevna |
The dynamics of the incidence of vaccine-controlled infections in the southern federal district of the russian federation from 2010 to 2023 |
| 11:15-15:00 | BREAK |
Session 1. Cancer Vaccines, Immunotherapy and Immunoprevention
Session 5. Advancement in Vaccine Design for Broad Protection
Date: 27th November 2024 (Wednesday)
Time: 15:00 (CET, Basel) | 09:00 (EDT, New York) | 22:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 15:00-15:15 | Prof. Dr. Mona O. Mohsen Session Chair |
Welcome from the Session Chair |
| 15:15-15:45 | Professor Roger Geiger Invited Speaker |
Metabolic modulation of tumors with engineered bacteria for cancer immunotherapy |
| 15:45-16:15 | Prof. Dr. Eva Sevick Keynote Speaker |
Improving checkpoint blockade immunotherapy with vaccination and lymphatic delivery |
| 16:15-16:30 | Romano Josi | Intranasal administration of a tetravalent nanovaccine inhibits growth of HPV-associated head and neck orthotopic tumors in a murine model |
| 16:30-16:45 | Arnau Solé Casaramona | Cutting-Edge: Unleashing the Potential of γδ T Cells with Novel Nanoparticles for Cancer Immunotherapy Applications |
| 16:45-17:05 | Professor Seth Pincus Invited Speaker |
Using Cytotoxic Immunoconjugates to Eradicate Persistent Viral Reservoirs |
| 17:05-17:20 | Silvia A. Sousa | Exploiting surface-exposed proteins to develop new therapeutic strategies against Bcc and Pseudomonas aeruginosa infections |
| 17:20-17:35 | Veronica Araceli Marquez-Escobar | Synthesis and characterization of zein nanoparticles for antigen delivery |
IECV 2024 Day 2
Session 3. Vaccine Adjuvants
Date: 28th November 2024 (Thursday)
Time: 9:00 (CET, Basel) | 03:00 (EDT, New York) | 16:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 09:00-09:10 | Prof. Dr. Silvio Tafuri & Dr. Srinivasa Reddy Bonam Session Chairs |
Welcome from the Session Chairs |
| 09:10-09:40 | Dr. Antonio Di Lorenzo Keynote Speaker |
The role of adjuvants in the vaccination of older adults with frailty conditions |
| 09:40-09:55 | Fusako Mitsunaga | Efficacy, Safety, and Molecular Mechanism of Sublingual Poly(I:C)-Adjuvanted Vaccine Formulated with SARS-CoV-2 RBD or Influenza HA Antigen in Non-Human Primates, Macaque Monkeys |
| 09:55-10:10 | Kishore Alugupalli | Turbo: an adjuvant platform for bacterial glycoconjugate vaccines |
| 10:10-10:25 | Xinliang Kang | Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant |
| 10:25-14:00 | BREAK |
Session 6. Novel Assays for Evaluating Responses to Vaccination
Date: 28th November 2024 (Thursday)
Time: 14:00 (CET, Basel) | 08:00 (EDT, New York) | 21:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 14:00-14:10 | Prof. Dr. Seth Pincus & Dr. Tan Yee Joo Session Chairs |
Welcome from the Session Chairs |
| 14:10-14:30 | Dr. Tan Yee Joo Keynote Speaker |
Establishing surrogate assays to measure antibodies inhibiting multiple subtypes of influenza A virus |
| 14:30-15:00 | Dr. Paul Engeroff Invited Speaker |
Allergy Immunotherapy: Considering Immune Complexes |
| 15:00-15:15 | Milagros Virhuez Mendoza | Distinguishing the antibodies induced by the live attenuated vaccine (LC16m8) and orthopoxvirus infections |
| 15:15-15:30 | Valeria Perniola |
Covid-19, influenza, and pneumococcus vaccinal status among hospitalized patients during the Covid-19 pandemic era |
| 15:30-15:45 | Zilu Ma | Immunoreactivity Analysis of MHC-I Epitopes Derived from the Nucleocapsid Protein of SARS-CoV-2 via Vaccination |
| 15:45-16:00 | Alvaro Munaylla | In silico design of a vaccine candidate against Oropouche virus based on a multi-epitope protein |
IECV 2024 Day 3
Session 4. mRNA Vaccines
Session 2. Challenges of Developing a Dengue Vaccine
Date: 29th November 2024 (Friday)
Time: 14:00 (CET, Basel) | 08:00 (EDT, New York) | 21:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 14:00-14:10 | Dr. Jorge H. Leitão & Dr. Srinivasa Reddy Bonam Session Chairs |
Welcome from the Session Chairs |
| 14:10-14:40 | Professor Gerald Barry Invited Speaker |
Analysis of bovine coronavirus sequences circulating in Ireland and development of a prototype, species specific, mRNA vaccine, targeting this virus |
| 14:40-14:55 | Rabaï Bouderhem | Regulating the use of AI in mRNA vaccine development through policy coherence |
| 14:55-15:10 | Noe Juvenal Mendoza-Ramírez | DNA immunization with a plasmid that codifies O-SN SARS-CoV-2 fusion protein induced effective humoral and cellular immune response in a preclinical model |
| 15:10-15:15 | Dr. Henry Puerta-Guardo & Dr. Bapi Pahar Session Chairs |
Welcome from the Session Chairs |
| 15:15-15:35 | Dr. Henry Puerta-Guardo Session Chair |
Challenges of Developing a Dengue Vaccine: a state of the art |
| 15:35-16:05 | Dr. Byron Martina Keynote Speaker |
The role of antibody glycosylation in dengue virus enhancement |
| 16:05-16:20 | Hector Hernando Gutierrez Barbosa | A comparison of Humanized mice models using NOD-derived strains for Dengue virus infection |
| 16:20-16:35 | Arturo Linan-Torres |
Development of a dual vaccine candidate against dengue and zika viruses by presenting a mimotope on the capsid of adeno-associated virus serotype 8 |